Seminoma clinical trials

The registry lists 63 studies for Seminoma across more than 10 countries. 15 are recruiting or about to start. 18 of them are mainly about Seminoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26.

Get an email when these change. Save the Seminoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 33
Recruiting: 14
Active, not recruiting: 7
Status unknown: 4
Terminated: 4
Not yet recruiting: 1

Phase

Phase 2: 29
Phase 3: 15
Phase 1: 5

Where

United States: 31
United Kingdom: 12
Germany: 9
France: 9
Canada: 7
Netherlands: 6

Who runs them

Fred Hutchinson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (6) · National Cancer Institute (NCI) (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Alliance for Clinical Trials in Oncology (2) · N.N. Petrov National Medical Research Center of Oncology (2) · City of Hope Medical Center (2) · Medical Research Council (2)

What is being tested here

Drugs under test in Seminoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Etoposide	1	2	6
Cisplatin	1	1	5
Carboplatin	0	2	6
Paclitaxel	0	2	6
Ifosfamide	0	1	5
Filgrastim	0	0	3
Ipilimumab	0	0	2
Pegfilgrastim	0	0	2
Imatinib	0	0	2
Tremelimumab	0	0	1

Drug classes tested here Antimitotic agents 8 · Tyrosine kinase inhibitors (TKIs) 5 · Alkylating agents 5 · Immune checkpoint inhibitors 3

Coming up

2phase 3 studies under way

6studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

May 2027Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer · Phase 3 · St. Olavs Hospital
Nov 2026Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors · Memorial Sloan Kettering Cancer Center
Dec 2026Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma · University of Southern California
Dec 2026Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma · Swiss Cancer Institute
Dec 2026MicroRNA as Markers in Testicular Cancer · Haukeland University Hospital
Jan 2027A Study of miRNA 371 in Patients With Germ Cell Tumors · SWOG Cancer Research Network

Who these studies take

Of the 14 Seminoma studies recruiting now, 9 (64%) set no upper age limit and 2 (14%) stop at 75 or younger. 1 (7%) take children under 18. 0 (0%) are for women only and 13 (93%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 14
Age	Women	Men
10	0 (0%)	0 (0%)
18	1 (7%)	14 (100%)
30	1 (7%)	14 (100%)
40	1 (7%)	14 (100%)
50	1 (7%)	14 (100%)
65	1 (7%)	13 (93%)
75	1 (7%)	12 (86%)
85	1 (7%)	11 (79%)

Across all 63 studies, recruiting or not: 25% stop at 75 or younger and 13% at 65; 46% take children; 0% are for women only and 52% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 63. Browse all 63 → or search them.